// App-Quantinova.ai

: The Effect of Protease-Activated Receptor-1 Inhibition With Vorapaxar in Post-mi and Nstemi Patients on Selected Biomarkers Reflecting Endothelial Function

Researchers

Presenter

  • Dennis W Nilsen

Principal Investigators

  • Michelle Røysland

  • Thor Ueland

  • Pal Aukrust

  • Annika E Michelsen

  • Harry Staines

  • Ståle Barvik

  • Frederic Kontny

  • Jan Erik Nordrehaug

  • Vernon V Bonarjee

Medical Centers

  • University of Bergen, Bergen, Norway

  • Sigma Statistical Services, Balmullo, United Kingdom

  • Dept of Cardiology, STAVANGER UNIVERSITY HOSPITAL, Stavanger, Norway

  • STAVANGER UNIVERSITY HOSPITAL, Stavanger, Norway

  • Rsch Institute of Internal Medicine, OSLO UNIVERSITY HOSPITAL, Stavanger, Norway

  • Oslo University Hospital, Oslo, Norway

  • STAVANGER UNIVERSITY HOSPITAL, Stavanger, Norway

  • DRAMMEN HJERTESENTER, Drammen, Norway

  • Faculty of Medicine, Univ of Oslo, Oslo Univ Hosp, Oslo, Norway

Locations

  • Norway

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Central Nervous System (CNS)

Disease

  • Acute Coronary Syndromes

  • Coronary Artery Disease

  • Myocardial infarction

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Vorapaxar

  • Evithrom

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved